Author:
JLSJG San Juan-Galán, CMFA Fernández, GFMM Martínez, MTIZ Illnait, MRPL Perurena, REVM Velar
Author address:
Bacteriology – Mycology, Institute of Tropical Medicine Pedro Kourí, Havana, Cuba
Full conference title:
9th Advances Against Aspergillosis
Date: 27 February 2020
Abstract:
Purpose: Aspergillosis is a fungal disease caused by different Aspergillus species and have high morbidity and mortality rates. Within the genus, A. fumigatus is the main aetiological agent related to most of Aspergillus infections. For management of aspergillosis the use of triazoles is recommended as first line of treatment, however, in the last few decades the reports of azole-resistant Aspergillus fumigatus due to mutation M220 and other aminoacidic substitutions in CYP51 have increased around the world. The goals of this study is to determine the antifungal susceptibility patterns for triazoles in 30 A. fumigatus isolates from clinical and environmental samples and to detect mutation M220 in the resistant ones.
Methods: With this purpose, the determination of minimum inhibitory concentrations of every isolate was performed by using the Etest commercial method (Biomérieux, France) for itraconazole, voriconazole and posaconazole. In the resistant isolates, a PCR was performed for amplifying a 173 bp fragment of cyp51A with chance of carrying the M220 mutation and the resulting amplicons were sequenced using Sanger methodology (Beckman Coulter, USA).
Results: Nine out of 30 isolates were resistant to itraconazole and none were resistant to voriconazole neither posaconazole. The sequences alignment with a CYP51 A. fumigatus wild type strain (Access number: Af293) did not show any modifications at codon 220.
Conclusion: Other molecular mechanisms of resistance must be evaluated according to the source of the isolates and new associations should be determine between epidemiological/ecological variables.
Abstract Number: 10
Link to conference website:
Link Conference abstract:
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a